Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108577 | 1.00 | AAK1 (0.50) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL9108583 | 1.00 | AAK1 (0.50) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL30231084 | 0.94 | AAK1 (0.46) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL24103537 | 0.94 | AAK1 (0.46) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL13576793 | 0.94 | AAK1 (0.46) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL29050430 | 0.92 | AAK1 (0.48) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL13622684 | 0.92 | AAK1 (0.48) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL30231048 | 0.92 | AAK1 (0.48) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL8282975 | 0.92 | AAK1 (0.48) | AAK1CA1CA2CA7CTSK | |
| SCHEMBL24181204 | 0.91 | KMT2A (0.51) | AAK1CA1CA2CA7CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | AAK1 2514/4885CA1 2491/4885CA2 1418/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | AAK1 2981/4885CA1 2027/4885CA2 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.